Singulair

Singulair has been on the market in the US since 1998.  Based statements made by Merck (the maker of Singulair), the FDA approved Singulair for children six months and older.  It treats hay fever, asthma and allergies.

The Harm

For decades, Merck has been receiving reports from patients taking Singulair.  Many reports told Merck that people who took Singulair experienced neuropsychiatric injuries.  These include obsessive compulsive disorder, anxiety, depression, tics, tremors, stuttering, and suicidality.  Nonetheless, Merck downplayed the risk of neuropsychiatric injuries.

The FDA

In March 2020, the FDA finally forced Merck to put a stronger warning on Singulair.  In fact, FDA required a “Black Box Warning,” which is the strongest kind.

Also, FDA issued a press release in March 2020.  Therein, an FDA spokesperson said, “We are taking this action after a review of available information ... Prescribing information already includes warnings about mental health side effects, including suicidal thoughts or actions; however, many health care professionals, patients and caregivers are not aware of the risk.”  In short, Merck has not been adequately warning anyone of the dangers of this drug.

The Law Suit

Beck Law Center is filing Singulair cases!  We have filed one in Wisconsin federal court and dozens in New Jersey state court.  Additionally, we have started discovery.  The litigation is rolling.